Slate Article: Psymposia – An NYT Story Blamed Leftists for Obstructing Psychedelic Therapy. The Truth Is Much More Infuriating. | Cannabis Law Report | How to order Skittles Moonrock online

Learn where to buy marijuana online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

Yes i thought that narrative of Psymposia as the bad guys for pointing out obvious truths was a fairly despicable article and was designed to serve the interests of capital. Never let a discussion of ethics get in the way of truckloads of cash!

As the Slate writer points out

As a journalist who has followed the psychedelics movement for years and attended hearings during the FDA approval process to write about them for Slate, the story was stunning. It was largely divorced from the events as I witnessed them, misleading in crucial ways, and journalistically bewildering.

Painting the FDA as easily corruptible may serve RFK Jr.’s agenda of eliminating oversight that keeps us all safe.

On Feb. 4—the same day that Robert F. Kennedy Jr.’s nomination for secretary of Health and Human Services advanced out of the Senate finance committee—the New York Times published a story with the headline “How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy.” The story claims that Psymposia, a psychedelic-science and harm-reduction nonprofit consisting of five members with no paid employees, used baseless and misleading accusations to thwart Food and Drug Administration approval of MDMA-assisted therapy, or MDMA-AT. Without the efforts of this “small band of anticapitalist activists,” the authors argue, Lykos Therapeutics’ “$250 million investment” in MDMA-AT may have paid off by being the first psychedelic therapy to get federal approval—potentially establishing the company as a multibillion-dollar enterprise.

As a journalist who has followed the psychedelics movement for years and attended hearings during the FDA approval process to write about them for Slate, the story was stunning. It was largely divorced from the events as I witnessed them, misleading in crucial ways, and journalistically bewildering. But what the story lacks in fully recounting why Lykos’ application tanked, it makes up for in fostering outrage, scapegoating a fringe group, and establishing a useful narrative should the new HHS secretary want to reverse the FDA’s decision.

The core argument about Psymposia outlined in the New York Times article—that individuals from the organization deliberately raised baseless, inflammatory allegations in a vendetta against Lykos and veterans—isn’t new. It’s an allegation initially posited by the Heroic Hearts Project, an organization that advocates for veterans’ access to psychedelic therapy. RFK Jr. retweeted that statement, and proponents of Lykos’ therapy later echoed the narrative in a video posted on the social media accounts of Lykos’ parent company, MAPS—the Multidisciplinary Association for Psychedelic Studies.

Read full article

https://slate.com/technology/2025/03/rfk-jr-mdma-psychedelic-therapy-new-york-times-lykos-fda-approval.html